Gastrointestinal hormones and the regulation of β-cell mass

Annals of the New York Academy of Sciences

Volumn 1212, Issue , 2010, Pages 41-58

  Lavine, Jeremy A ^a   Attie, Alan D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

CCK; Gastrin; GIP; GLP 1; Islet; Protein kinase B Akt; cell

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL;

EID: 78649471913     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05802.x     Document Type: Article

References (127)

1. Baggio, L.L. & D.J. Drucker 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology. 132: 2131-2157.
2. Dufresne, M., C. Seva & D. Fourmy 2006. Cholecystokinin and gastrin receptors. Physiol. Rev. 86: 805-847.
3. Karlsson, S. & B. Ahren 1992. CCK-8-stimulated insulin secretion in vivo is mediated by CCKA receptors. Eur. J. Pharmacol. 213: 145-146.
4. Ahren, B., M. Pettersson, K. Uvnas-Moberg, et al 1991. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. Diabetes Res. Clin. Pract. 13: 153-161.
5. Hildebrand, P., J.W. Ensinck, S. Ketterer, et al 1991. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. J. Clin. Endocrinol. Metab. 72: 1123-1129.
6. Ahren, B., J.J. Holst & S. Efendic 2000. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J. Clin. Endocrinol. Metab. 85: 1043-1048.
7. Matveyenko, A.V. & P.C. Butler 2008. Relationship between beta-cell mass and diabetes onset. Diabetes Obes. Metab. 10(Suppl 4): 23-31.
8. Henquin, J.C., E. Cerasi, S. Efendic, et al 2008. Pancreatic beta-cell mass or beta-cell function? That is the question!. Diabetes Obes. Metab. 10(Suppl 4): 1-4.
9. Butler, A.E., J. Janson, S. Bonner-Weir, et al 2003. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52: 102-110.
10. Hanley, S.C., E. Austin, B. Assouline-Thomas, et al 2010. {beta}-Cell Mass Dynamics and Islet Cell Plasticity in Human Type 2 Diabetes. Endocrinology. 151: 1462-1472.
11. Rahier, J., Y. Guiot, R.M. Goebbels, et al 2008. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes. Metab. 10(Suppl 4): 32-42.
12. Ritzel, R.A., A.E. Butler, R.A. Rizza, et al 2006. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care. 29: 717-718.
13. Kloppel, G., M. Lohr, K. Habich, et al 1985. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv. Synth. Pathol. Res. 4: 110-125.
14. Perfetti, R., J. Zhou, M.E. Doyle & J.M. Egan 2000. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 141: 4600-4605.
15. Buteau, J., M.L. Spatz & D. Accili 2006. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes. 55: 1190-1196.
16. Li, Y., X. Cao, L.X. Li, et al 2005. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54: 482-491.
17. Park, S., X. Dong, T.L. Fisher, et al 2006. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 281: 1159-1168.
18. Song, W.J., W.E. Schreiber, E. Zhong, et al 2008. Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes 57: 2371-2381.
19. Tschen, S.I., S. Dhawan, T. Gurlo & A. Bhushan 2009. Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 58: 1312-1320.
20. Kwon, D.Y., Y.S. Kim, I.S. Ahn, et al 2009. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J. Pharmacol. Sci. 111: 361-371.
21. Xu, G., D.A. Stoffers, J.F. Habener & S. Bonner-Weir 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
22. Wang, Z.V., J. Mu, T.D. Schraw, et al 2008. PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. Diabetes 57: 2137-2148.
23. Zhang, J., Y. Tokui, K. Yamagata, et al 2007. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50: 1900-1909.
24. Perez-Arana, G., Blandino-Rosano, M., Prada-Oliveira, A., et al 2010. Decrease in {beta}-cell proliferation precedes apoptosis during diabetes development in bio-breeding/worcester rat: beneficial role of Exendin-4. Endocrinology 151: 2538-2546.
25. Green, B.D., K.S. Lavery, N. Irwin, et al 2006. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J. Pharmacol. Exp. Ther. 318: 914-921.
26. Cheng, Q., P.K. Law, M. De Gasparo & P.S. Leung 2008. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1, 1'-biphenyl]-4-yl]methyl]-L- valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J. Pharmacol. Exp. Ther. 327: 683-691.
27. Kim, J.G., L.L. Baggio, D.P. Bridon, et al 2003. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52: 751-759.
28. Ma, X., H. Hui, Z. Liu, et al 2009. Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation. Diabetes Obes. Metab. 11: 953-965.
29. Wang, Q. & P.L. Brubaker 2002. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45: 1263-1273.
30. Farilla, L., H. Hui, C. Bertolotto, et al 2002. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-4408.
31. Takiguchi, S., Y. Takata, A. Funakoshi, et al 1997. Disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. Gene 197: 169-175.
32. Wang, Y. & X.H. Guo 2006. [Effects of GLP-1 treatment on protection of B cells in Otsuka Long-Evans Tokushima fatty rats. Beijing Da Xue Xue Bao. 38: 375-380.
33. Li, Y., C. Shi, Q. Lv, et al 2008. GLP-1 C-terminal structures affect its blood glucose lowering-function. J. Pept. Sci. 14: 777-785.
34. Mu, J., A. Petrov, G.J. Eiermann, et al 2009. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur. J. Pharmacol. 623: 148-154.
35. Ling, Z., D. Wu, Y. Zambre, et al 2001. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 438: 382-387.
36. De Leon, D.D., S. Deng, R. Madani, et al 2003. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52: 365-371.
37. Dor, Y., J. Brown, O.I. Martinez & D.A. Melton 2004. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429: 41-46.
38. Scrocchi, L.A., M.E. Hill, J. Saleh, et al 2000. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes 49: 1552-1560.
39. Anini, Y. & P.L. Brubaker 2003. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52: 252-259.
40. Friedrichsen, B.N., N. Neubauer, Y.C. Lee, et al 2006. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J. Endocrinol. 188: 481-492.
41. Kim, M.J., J.H. Kang, Y.G. Park, et al 2006. Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element. J. Endocrinol. 188: 623-633.
42. He, L.M., D.J. Sartori, M. Teta, et al 2009. Cyclin D2 protein stability is regulated in pancreatic beta-cells. Mol. Endocrinol. 23: 1865-1875.
43. Buteau, J., R. Roduit, S. Susini & M. Prentki 1999. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856-864.
44. Lawlor, M.A. & D.R. Alessi 2001. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses. J. Cell Sci. 114: 2903-2910.
45. Wang, Q., L. Li, E. Xu, et al 2004. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47: 478-487.
46. Stoffers, D.A., B.M. Desai, D.D. DeLeon & R.A. Simmons 2003. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52: 734-740.
47. Jhala, U.S., G. Canettieri, R.A. Screaton, et al 2003. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 17: 1575-1580.
48. Withers, D.J., J.S. Gutierrez, H. Towery, et al 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391: 900-904.
49. Buteau, J., S. Foisy, E. Joly & M. Prentki 2003. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132.
50. Buteau, J., S. Foisy, C.J. Rhodes, et al 2001. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50: 2237-2243.
51. Le Good, J.A., W.H. Ziegler, D.B. Parekh, et al 1998. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281: 2042-2045.
52. Furukawa, N., T. Shirotani, E. Araki, et al 1999. Possible involvement of atypical protein kinase C (PKC) in glucose-sensitive expression of the human insulin gene: DNA-binding activity and transcriptional activity of pancreatic and duodenal homeobox gene-1 (PDX-1) are enhanced via calphostin C-sensitive but phorbol 12-myristate 13-acetate (PMA) and Go 6976-insensitive pathway. Endocr. J. 46: 43-58.
53. Blandino-Rosano, M., G. Perez-Arana, J.M. Mellado-Gil, et al 2008. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. J. Mol. Endocrinol. 41: 35-44.
54. Trumper, J., D. Ross, H. Jahr, et al 2005. The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells. Diabetologia 48: 1534-1540.
55. Briaud, I., M.K. Lingohr, L.M. Dickson, et al 2003. Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic beta-cells. Diabetes 52: 974-983.
56. Welters, H.J. & R.N. Kulkarni 2008. Wnt signaling: relevance to beta-cell biology and diabetes. Trends Endocrinol. Metab. 19: 349-355.
57. Liu, Z. & J.F. Habener 2008. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem. 283: 8723-8735.
58. Rulifson, I.C., S.K. Karnik, P.W. Heiser, et al 2007. Wnt signaling regulates pancreatic beta cell proliferation. Proc. Natl Acad. Sci. USA 104: 6247-6252.
59. Miyawaki, K., Y. Yamada, N. Ban, et al 2002. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8: 738-742.
60. Gault, V.A., N. Irwin, B.D. Green, et al 2005. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54: 2436-2446.
61. Irwin, N., G.C. Clarke, B.D. Green, et al 2006. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem. Pharmacol. 72: 719-728.
62. Kidd, G.S., Donowitz, M., O'Dorisio, T., et al 1979. Mild chronic watery diarrhea-hypokalemia syndrome associated with pancreatic islet cell hyperplasia. Elevated plasma and tissue levels of gastric inhibitory polypeptide and successful management with nicotinic acid. Am. J. Med. 66: 883-888.
63. Ehses, J.A., V.R. Casilla, T. Doty, et al 2003. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144: 4433-4445.
64. Trumper, A., K. Trumper & D. Horsch 2002. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 174: 233-246.
65. Trumper, A., K. Trumper, H. Trusheim, et al 2001. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15: 1559-1570.
66. Ehses, J.A., S.L. Pelech, R.A. Pederson & C.H. McIntosh 2002. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J. Biol. Chem. 277: 37088-37097.
67. Kuntz, E., M. Pinget & P. Damge 2004. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. JOP 5: 464-475.
68. Chen, S., S. Turner, E. Tsang, et al 2007. Measurement of pancreatic islet cell proliferation by heavy water labeling. Am. J. Physiol. Endocrinol. Metab. 293: E1459-E1464.
69. Shima, K., M. Zhu & A. Mizuno 1999. Pathoetiology and prevention of NIDDM lessons from the OLETF rat. J. Med. Invest. 46: 121-129.
70. Brelje, T.C. & R.L. Sorenson 1991. Role of prolactin versus growth hormone on islet B-cell proliferation in vitro: implications for pregnancy. Endocrinology 128: 45-57.
71. Lavine, J.A., P.W. Raess, D.B. Davis, et al 2010. Contamination with E1A-positive wild-type adenovirus accounts for species-specific stimulation of islet cell proliferation by CCK: a cautionary note. Mol. Endocrinol. 24: 464-467.
72. Parmar, N.S., M. Tariq & A.M. Ageel 1987. Proglumide, a cholecystokinin receptor antagonist, exacerbates alloxan-induced diabetes mellitus in Swiss mice. J. Pharm. Pharmacol. 39: 1028-1030.
73. Meier, J.J., A.E. Butler, R. Galasso, et al 2006. Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia. 49: 2689-2696.
74. Nir, T., D.A. Melton & Y. Dor 2007. Recovery from diabetes in mice by beta cell regeneration. J. Clin. Invest. 117: 2553-2561.
75. Inada, A., C. Nienaber, H. Katsuta, et al 2008. Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc. Natl. Acad. Sci. USA 105: 19915-19919.
76. Solar, M., C. Cardalda, I. Houbracken, et al 2009. Pancreatic exocrine duct cells give rise to insulin-producing beta cells during embryogenesis but not after birth. Dev. Cell. 17: 849-860.
77. Thorel, F., V. Nepote, I. Avril, et al 2010. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464: 1149-1154.
78. Tourrel, C., D. Bailbe, M.J. Meile, et al 2001. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50: 1562-1570.
79. Suarez-Pinzon, W.L., R.F. Power, Y. Yan, et al 2008. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57: 3281-3288.
80. Lee, J., J. Wen, J.Y. Park, et al 2009. Reversal of diabetes in rats using GLP-1-expressing adult pancreatic duct-like precursor cells transformed from acinar to ductal cells. Stem Cells Dev. 18: 991-1002.
81. Suarez-Pinzon, W.L., J.R. Lakey & A. Rabinovitch 2008. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant. 17: 631-640.
82. Bulotta, A., H. Hui, E. Anastasi, et al 2002. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J. Mol. Endocrinol. 29: 347-360.
83. Hui, H., C. Wright & R. Perfetti 2001. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50: 785-796.
84. Mao, G.H., G.A. Chen, H.Y. Bai, et al 2009. The reversal of hyperglycaemia in diabetic mice using PLGA scaffolds seeded with islet-like cells derived from human embryonic stem cells. Biomaterials 30: 1706-1714.
85. Yue, F., L. Cui, K. Johkura, et al 2006. Glucagon-like peptide-1 differentiation of primate embryonic stem cells into insulin-producing cells. Tissue Eng. 12: 2105-2116.
86. Herbach, N., B. Goeke, M. Schneider, et al 2005. Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development. Regul. Pept. 125: 103-117.
87. McClean, P.L., V.A. Gault, N. Irwin, et al 2008. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. Diabetes Obes. Metab. 10: 336-342.
88. Marenah, L., J.T. McCluskey, Y.H. Abdel-Wahab, et al 2006. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biol. Chem. 387: 941-947.
89. Wang, T.C., S. Bonner-Weir, P.S. Oates, et al 1993. Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J. Clin. Invest. 92: 1349-1356.
90. Gigoux, V., P. Clerc, D. Sanchez, et al 2008. Reg genes are CCK2 receptor targets in ElasCCK2 mice pancreas. Regul. Pept. 146: 88-98.
91. Rooman, I., J. Lardon & L. Bouwens 2002. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 51: 686-690.
92. Rooman, I. & L. Bouwens 2004. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia 47: 259-265.
93. Brand, S.J., S. Tagerud, P. Lambert, et al 2002. Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin. Pharmacol. Toxicol. 91: 414-420.
94. Suarez-Pinzon, W.L., J.R. Lakey, S.J. Brand & A. Rabinovitch 2005. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. J. Clin. Endocrinol. Metab. 90: 3401-3409.
95. Hardikar, A.A., X.Y. Wang, L.J. Williams, et al 2002. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 143: 3505-3514.
96. Li, Y., T. Hansotia, B. Yusta, et al 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278: 471-478.
97. Maida, A., T. Hansotia, C. Longuet, et al 2009. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 137: 2146-2157.
98. Yusta, B., L.L. Baggio, J.L. Estall, et al 2006. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 4: 391-406.
99. Uckaya, G., P. Delagrange, A. Chavanieu, et al 2005. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue. J. Endocrinol. 184: 505-513.
100. Lin, C.C. & K.S. Anseth 2009. Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells. Biomacromolecules 10: 2460-2467.
101. Merani, S., W. Truong, J.A. Emamaullee, et al 2008. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology 149: 4322-4328.
102. Toyoda, K., T. Okitsu, S. Yamane, et al 2008. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem. Biophys. Res. Commun. 367: 793-798.
103. Faradji, R.N., T. Tharavanij, S. Messinger, et al 2008. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation 86: 1658-1665.
104. Froud, T., R.N. Faradji, A. Pileggi, et al 2008. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 86: 36-45.
105. Gangemi, A., P. Salehi, B. Hatipoglu, et al 2008. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am. J. Transplant. 8: 1250-1261.
106. Cornu, M., J.Y. Yang, E. Jaccard, et al 2009. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 58: 1816-1825.
107. Wideman, R.D., I.L. Yu, T.D. Webber, et al 2006. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl Acad. Sci. USA 103: 13468-13473.
108. Bregenholt, S., A. Moldrup, N. Blume, et al 2005. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330: 577-584.
109. Sarkar, S.A., J. Gunter, R. Bouchard, et al 2007. Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets. Diabetologia 50: 1649-1659.
110. Ferdaoussi, M., S. Abdelli, J.Y. Yang, et al 2008. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 57: 1205-1215.
111. Bonny, C., A. Oberson, M. Steinmann, et al 2000. IB1 reduces cytokine-induced apoptosis of insulin-secreting cells. J. Biol. Chem. 275: 16466-16472.
112. Waeber, G., J. Delplanque, C. Bonny, et al 2000. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat. Genet. 24: 291-295.
113. Haefliger, J.A., T. Tawadros, L. Meylan, et al 2003. The scaffold protein IB1/JIP-1 is a critical mediator of cytokine-induced apoptosis in pancreatic beta cells. J. Cell Sci. 116: 1463-1469.
114. Xie, T., M. Chen, Q.H. Zhang, et al 2007. Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. Proc. Natl Acad. Sci. USA 104: 19601-19606.
115. Li, L., W. El-Kholy, C.J. Rhodes & P.L. Brubaker 2005. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 48: 1339-1349.
116. Cornu, M., H. Modi, D. Kawamori, et al 2010. Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. J. Biol. Chem. 285: 10538-10545.
117. Tsunekawa, S., N. Yamamoto, K. Tsukamoto, et al 2007. Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J. Endocrinol. 193: 65-74.
118. Buteau, J., W. El-Assaad, C.J. Rhodes, et al 2004. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47: 806-815.
119. Widenmaier, S.B., A.V. Sampaio, T.M. Underhill & C.H. McIntosh 2009. Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J. Biol. Chem. 284: 10764-10773.
120. Hui, H., A. Nourparvar, X. Zhao & R. Perfetti 2003. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144: 1444-1455.
121. Widenmaier, S.B., Kim, S.J., Yang, G.K., et al 2010. A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One 5: e9590.
122. Kim, S.J., K. Winter, C. Nian, et al 2005. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J. Biol. Chem. 280: 22297-22307.
123. Kim, S.J., C. Nian, S. Widenmaier & C.H. McIntosh 2008. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol. Cell Biol. 28: 1644-1656.
124. Widenmaier, S.B., Z. Ao, S.J. Kim, et al 2009. Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J. Biol. Chem. 284: 30372-30382.
125. Huang, Q., S. Bu, Y. Yu, et al 2007. Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase. Endocrinology 148: 81-91.
126. Zhao, J., N. Zhang, M. He, et al 2008. Increased beta-cell apoptosis and impaired insulin signaling pathway contributes to the onset of diabetes in OLETF rats. Cell Physiol. Biochem. 21: 445-454.
127. Lavine, J.A., P.W. Raess, D.S. Stapleton, et al 2010. Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology 151: 3577-3588.